Sean Harper - Amgen Insider

Amgen Inc -- USA Stock  

USD 186.11  0.18  0.10%

Executive Vice President - Research and Development

Dr. Sean E. Harper is the Executive Vice President Research and Development of Amgen Inc. Dr. Harper joined the Company in 2002, and has held leadership roles in early development, medical sciences and global regulatory and safety
Age: 53  President Since 2012  Ph.D    
805 447-1010  www.amgen.com
Harper served as Senior Vice President, Global Development and Corporationrationrationrate Chief Medical Officer from March 2007 to February 2012. Prior to joining the Company, Dr. Harper worked for five years at Merck Research Laboratories.

Management Efficiency

The company has return on total asset (ROA) of 8.27 % which means that it generated profit of $8.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 26.43 % meaning that it created $26.43 on every $100 dollars invested by stockholders.
The company currently holds 35.06 B in liabilities with Debt to Equity (D/E) ratio of 110.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 6.08 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Jared WatkinAbbott Laboratories
2015
Eric FainAbbott Laboratories
2017
Timothy ErnstBio Rad Laboratories Inc
2016
Stephen FussellAbbott Laboratories
2013
Georges VosAbbott Laboratories
2013
Daniel SalvadoriAbbott Laboratories
2014
Charles FoltzAbbott Laboratories
2013
Thomas FrinziAbbott Laboratories
2016
Andrew LaneAbbott Laboratories
2015
Heather MasonAbbott Laboratories
2015
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Scott WhiteAbbott Laboratories
2013
Robert StewartAllergan plc
2016
John HertiaBio Rad Laboratories Inc
2014
Paul SilvaVertex Pharmaceuticals Incorpor
2011
Michael WarmuthAbbott Laboratories
2012
Amit SachdevVertex Pharmaceuticals Incorpor
2017
Robert FunckAbbott Laboratories
2013
Matthew MalettaEndo International plc
2015
Michael CrowleyBio Rad Laboratories Inc
2014
Antonio PeraEndo International plc
2016

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 17,900 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio Reporting Now
   

Portfolio Reporting

Create custom reports across your portfolios and generate quick suggestion pitch
Hide  View All  Next  Launch Portfolio Reporting
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
R Williams, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators